Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma

被引:28
作者
Bendardaf, R
Ristamäki, R
Kujari, H
Laine, J
Lamlum, H
Collan, Y
Pyrhönen, S
机构
[1] Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland
[2] Univ Turku, Cent Hosp, Dept Radiotherapy & Oncol, FIN-20520 Turku, Finland
[3] Univ Turku, Cent Hosp, Dept Pathol, FIN-20520 Turku, Finland
关键词
colorectal carcinoma; apoptosis; bcl-2; carcinoembryonic antigen; 5-fluorouracil; irinotecan; survival;
D O I
10.1159/000070304
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: To examine programmed cell death in 57 colorectal carcinomas (49 primary tumours and 8 metastases) and determine the prognostic significance of apoptosis in colorectal cancer. Methods: Apoptotic index (Al) was ascertained by counting apoptotic bodies, using terminal deoxynucleotidyl transferase mediated digoxigenin nick end labelling (Tunel assay) and the expression of bcl-2 was examined immunohistochemically. Statistical analysis was used to test the value of clinical variables, histopathological data, Al and bcl-2 expression in predicting the clinical outcome of these patients and the survival function was calculated using the Kaplan-Meier method. Results: Al was found to have a significant independent effect on survival (p = 0.0006), with lower values of Al conveying better survival. Conclusion: In summary, these findings reveal that Al is a useful prognostic factor in colorectal carcinoma.
引用
收藏
页码:435 / 442
页数:8
相关论文
共 35 条
[1]   CARCINOEMBRYONIC ANTIGEN, A HUMAN-TUMOR MARKER, FUNCTIONS AS AN INTERCELLULAR-ADHESION MOLECULE [J].
BENCHIMOL, S ;
FUKS, A ;
JOTHY, S ;
BEAUCHEMIN, N ;
SHIROTA, K ;
STANNERS, CP .
CELL, 1989, 57 (02) :327-334
[2]   BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL-DEATH [J].
BOISE, LH ;
GONZALEZGARCIA, M ;
POSTEMA, CE ;
DING, LY ;
LINDSTEN, T ;
TURKA, LA ;
MAO, XH ;
NUNEZ, G ;
THOMPSON, CB .
CELL, 1993, 74 (04) :597-608
[3]   Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer [J].
Cunningham, D ;
Pyrhönen, S ;
James, RD ;
Punt, CJA ;
Hickish, TF ;
Heikkila, R ;
Johannesen, TB ;
Starkhammar, H ;
Topham, CA ;
Awad, L ;
Jacques, C ;
Herait, P .
LANCET, 1998, 352 (9138) :1413-1418
[4]  
DESCHNER E, 1990, KINETICS NORMAL PREN
[5]   Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].
Douillard, JY ;
Cunningham, D ;
Roth, AD ;
Navarro, M ;
James, RD ;
Karasek, P ;
Jandik, P ;
Iveson, T ;
Carmichael, J ;
Alakl, M ;
Gruia, G ;
Awad, L ;
Rougier, P .
LANCET, 2000, 355 (9209) :1041-1047
[6]  
Evertsson S, 1999, INT J ONCOL, V15, P53
[7]   The biology of apoptosis [J].
Geske, FJ ;
Gerschenson, LE .
HUMAN PATHOLOGY, 2001, 32 (10) :1029-1038
[8]   BCL-2 IS AN INNER MITOCHONDRIAL-MEMBRANE PROTEIN THAT BLOCKS PROGRAMMED CELL-DEATH [J].
HOCKENBERY, D ;
NUNEZ, G ;
MILLIMAN, C ;
SCHREIBER, RD ;
KORSMEYER, SJ .
NATURE, 1990, 348 (6299) :334-336
[9]   CARCINOEMBRYONIC ANTIGEN AS A SELECTIVE ENHANCER OF COLORECTAL-CANCER METASTASIS [J].
HOSTETTER, RB ;
AUGUSTUS, LB ;
MANKARIOUS, R ;
CHI, KF ;
FAN, D ;
TOTH, C ;
THOMAS, P ;
JESSUP, JM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (05) :380-385
[10]  
Kawasaki H, 2001, CANCER, V91, P2026, DOI 10.1002/1097-0142(20010601)91:11<2026::AID-CNCR1228>3.0.CO